Tenax Therapeutics (NASDAQ:TENX) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a report issued on Friday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

TENX has been the subject of several other reports. Leerink Partners set a $20.00 price objective on Tenax Therapeutics in a research report on Monday, March 10th. William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Tenax Therapeutics Price Performance

NASDAQ:TENX opened at $6.57 on Friday. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $7.89. The stock has a 50-day moving average price of $6.44 and a two-hundred day moving average price of $5.34.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC bought a new stake in Tenax Therapeutics in the 4th quarter valued at approximately $1,026,000. Vestal Point Capital LP bought a new position in shares of Tenax Therapeutics during the 3rd quarter worth approximately $288,000. Stonepine Capital Management LLC acquired a new stake in shares of Tenax Therapeutics in the third quarter valued at approximately $173,000. Sphera Funds Management LTD. bought a new stake in shares of Tenax Therapeutics in the third quarter worth $101,000. Finally, Millennium Management LLC acquired a new position in Tenax Therapeutics during the fourth quarter worth $166,000. 1.67% of the stock is currently owned by institutional investors.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.